Endotis
Romainville
About Endotis
Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $41.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2008)
- Website: endotis.com
- Phone: 33 1 48 46 43 91
Industries & Categories
Biopharma, Biotechnology, Health Care, Manufacturing, Therapeutics
Canonical: https://fsome.com/organization/endotis-3694042 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.